The efficacy and safety of the domestic travoprost generic in various modes of therapy for primary open-angle glaucoma

PURPOSE. Comparative study of the efficacy and safety of the reproduced travoprost drug (generic) TravoprostOptic and the original drug (Travatan) in patients with primary open-angle glaucoma receiving mono- or combination therapy.

METHODS. A non-randomized prospective crossover study included 60 patients (60 eyes) with a diagnosis of stage I or II primary open-angle glaucoma, compensated by hypotensive therapy — monotherapy with the original travoprost drug (group 1, n=30), or combination therapy with the original travoprost drug (group 2, n=30). At the screening visit after the examination, the original travoprost was replaced by Travoprost-Optic in all patients. Efficacy was studied based on an assessment of the dynamics of intraocular pressure values, safety — based on an analysis of the severity of the main adverse effects of therapy using a special questionnaire before and 4 weeks after replacing the travoprost drug separately in each group.

RESULTS. In group 1 and group 2, the initial average level of intraocular pressure was 14.3±2.3 mm Hg and 16.2±1.1 mm Hg, respectively. In 4 weeks after replacing the original travoprost drug with Travoprost-Optic, there was no statistically significant dynamics of the indicator values in the groups — 13.7±2.7 mm Hg and 16.0±2.4 mm Hg, respectively. There were no significant differences in the severity of the adverse effects of antihypertensive therapy such as irritation, itching, lacrimation, foreign body sensation and dry eye.

CONCLUSION. The generic drug Travoprost-Optic, in comparison with the original travoprost, has a comparable efficacy and safety profile, as well as higher economic availability, and can be considered as an alternative.

1. Clinical guidelines «Primary open-angle glaucoma». Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2020.

2. Antonov A.A., Agadzhanyan T.M., Vitkov А.А. Hypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2019; 18(1):95-104. (In Russ.) doi:10.25700/NJG.2019.01.11

3. Karlova E.V., Lebedev O.I., Stoliarov G.M. Medication assisted activation of unveoscleral outflow of intraocular fluid in glaucoma: pathogenic aspects. Vestnik oftal’mologii. 2013; 129(4):83-87. (In Russ.)

4. Kiseleva O.A., Bessmertny A.M., Yakubova L.V., Iomdina E.N. et al. Efficiency and safety of Travapress in patients with primary openangle glaucoma. Vestnik oftal’mologii. 2019; 135(1):67-73. doi:10.17116/oftalma201913501167

5. Sharif N.A., Kelly C.R., Crider J.Y. et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2002; 19(6):501-15.

6. Yagudina R.I., Asestrov D.O., Serpik V.G. Pharmacoeconomic evaluation of use the drug travatan (travoprost) in the treatment of primary open-angle glaucoma FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2011; 4(4):75-79.

7. Shmyreva V.F., Petrov S.Yu., Antonov A.A., Danilov S.S. Study of diurnal fluctuations of IOP level in patients with POAG on the monotherapy of timolol, latanoprost and travoprost. RMJ Clinical Ophtamology. 2010; 12(4):125-127.

8. Travoprost looks best for the budget in glaucoma. Pharmacoecon. Outcomes News. 2009; 4:570. doi:10.2165/00151234-200905700-00008

9. Instructions for the medical use of the drug Travatan. Web resource: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=2a4ff07e-951b-42af-886d-08a40c070f1d&t= (accessed: 01.11.2021).

10. Order of the Government of the Russian Federation of October 12, 2019 No. 2406-r «On approval of the list of vital and essential drugs for 2020» (with changes and additions; came into force on 01.01.2021)

11. Order of the Ministry of Health of Russian Federation of February 13, 2013 No. 66 (as revised on 13.07.2021) «On approval of the Strategy for drug provision of the population of the Russian Federation for the period up to 2025 and the plan for its implementation»

12. Data from the State Register of Medicines. Web resource: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=%d0%a2%d1%80%d0%b0%d0%b2%d0%be%d0%bf%d1%80%d0%be%d1%81%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry= &isfs=0&regtype=1%2c6&pageSize=10&order=RegDate&orderType =desc&pageNum=1 (accessed 01.11.2021).

13. Instructions for the medical use of the drug Travoprost-Optic. Web resource: https://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=8717b236-c682-44b2-b438-7221c48a54e2&t= (accessed: 01.11.2021).

14. Federal Law of the Russian Federation «On the Circulation of Drugs» dated 12.04.2010 No. 61-FZ (as amended on 11.06.2021).

15. Decision of the Council of the Eurasian Economic Commission of 03.11.2016 No. 78 (as amended on 23.04.2021) «On the Rules for the registration and examination of medicines for medical use».

16. Tianjing Li, Kristina Lindsley, Benjamin Rouse et al. Comparative Effectiveness of First-line Medications for Primary Open Angle Glaucoma – A Systematic Review and Network Meta-analysis. Ophthalmology. 2016; 123(1):129–140. doi:10.1016/j.ophtha.2015.09.005

17. Reis R., Queiroz C.F., Santos L.C. et al. A randomized, investigatormasked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006; 28(4):552–559. doi:10.1016/j.clinthera.2006.04.007.

18. Stephen Boyer, Dax Gay. Additive effect of dorzolamide hydrochloride to patients taking travoprost: a retrospective study. Optometry. 2008; 79(9):501–504. doi:10.1016/j.optm.2008.01.019.

19. Babić N., Andreić V., Miljković A. et al. Adjunctive therapy with brinzolamide in patients on travoprost treatment. Med Pregl. 2011; 64(5–6): 310–314. doi:10.2298/mpns1106310b.

20. Wenquan Tang, Feng Zhang, Ke Liu et al. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients. Medicine. 2019; 98:30(e16597). doi:10.1097/MD.0000000000016597.